SB 529, the Capping Prescription Costs Act of 2025, would place a nationwide cap on out-of-pocket cost-sharing for prescription drugs covered by health plans. For plan years beginning in 2026, the bill limits prescription drug cost-sharing to $2,000 per enrolled individual and $4,000 per family each year. Beginning in 2027, those dollar limits would be indexed to the medical care component of the Consumer Price Index, with increases rounded down to the nearest $5.
The bill amends multiple federal statutes to make the cap apply across different types of coverage. It changes the Affordable Care Act’s rules for qualified health plans and adds parallel requirements for group health plans and health insurance issuers under the Public Health Service Act, the Employee Retirement Income Security Act (ERISA), and the Internal Revenue Code. The practical effect is to prohibit covered plans from charging prescription-drug cost-sharing above the federal cap, beginning with plan years on or after January 1, 2026.
Impact
The bill would directly alter the Affordable Care Act, the Public Health Service Act, ERISA, and the Internal Revenue Code by adding a uniform prescription-drug cost-sharing ceiling for covered health plans. It would affect insurers, employers sponsoring group health plans, and individuals enrolled in qualified health plans or employer-sponsored coverage by limiting annual out-of-pocket drug expenses and requiring plan design changes before the 2026 effective date.
Sentiment
Based on the bill text and the absence of recorded committee debate or votes in the provided materials, the measure appears to be framed as a consumer-cost relief proposal with an emphasis on lowering prescription drug expenses. The sponsorship by a group of Democratic senators suggests support from lawmakers favoring stronger affordability protections, and there is no evidence in the provided record of formal opposition or amendment activity.
Contention
The main policy issue likely to generate debate is the size and structure of the cap, including whether a $2,000 individual/$4,000 family limit is appropriate and how annual inflation indexing should work. Potential points of contention also include the bill’s broad application to employer-sponsored plans and the administrative and premium impacts on insurers and plan sponsors. Because the bill applies across multiple federal coverage regimes, stakeholders concerned about mandates, benefit design flexibility, and cost shifting may object, while consumer advocates and patients facing high drug costs would likely support it.
An Act to Direct the Maine Prescription Drug Affordability Board to Assess Strategies to Reduce Prescription Drug Costs and to Take Steps to Implement Reference-based Pricing
Enacting the prescription drug cost and affordability review act to establish the prescription drug pricing board and prescription drug affordability stakeholder council to review the cost of prescription medications and establish upper payment limits for certain prescription drugs.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a sixty-day (60) supply may be dispensed at any one time.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a ninety-day (90) supply may be dispensed at any one time.